

Haematologica
HAEMATOL/2019/219550
Version 3

Biological and clinical implications of BIRC3 mutations in chronic
lymphocytic leukemia

Fary Diop, Riccardo Moia, Chiara Favini, Elisa Spaccarotella, Lorenzo De Paoli, Alessio Bruscatto, Valeria Spina, Lodovico Terzi-di-Bergamo, Francesca Arruga, Chiara Tarantelli, Clara Deambrogi, Silvia Rasi, Ramesh Adhinaveni, Andrea Patriarca, Simone Favini, Sruthi Sagiraju, Clive Jabangwe, Ahad A. Kodipad, Denise Peroni, Francesca R. Mauro, Ilaria Del Giudice, Francesco Forconi, Agostino Cortelezzi, Francesco Zaja, Riccardo Bomben, Francesca Maria Rossi, Carlo Visco, Annalisa Chiarenza, Gian Matteo Rigolin, Roberto Marasca, Marta Coscia, Omar Perbellini, Alessandra Tedeschi, Luca Laurenti, Marina Motta, David Donaldson, Phil Weir, Ken Mills, Patrick Thornton, Sarah Lawless, Francesco Bertoni, Giovanni Del Poeta, Antonio Cuneo, Antonia Follenzi, Valter Gattei, Renzo Luciano Boldorini, Mark Catherwood, Silvia Deaglio, Robin Foá, Gianluca Gaidano, and Davide Rossi

Disclosures: This work was supported by: Molecular bases of disease dissemination in lymphoid malignancies to optimize curative therapeutic strategies, (5 x 1000 No. 21198), Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy (To GG and RF). Associazione Italiana per la Ricerca sul Cancro (AIRC IG-17314). Progetti di Rilevante Interesse Nazionale (PRIN), (2015ZMRFEA), Rome, Italy Partially funded by the AGING Project – Department of Excellence – DIMET, Università del Piemonte Orientale, Novara, Italy Partially funded by Novara AIL ONLUS, Novara, Italy Swiss cancer League, ID HSR-4660-11-2018, Bern, Switzerland; Research Advisory Board of the Ente Ospedaliero Cantonale, Bellinzona, Switzerland; European Research Council (ERC) Consolidator Grant CLLCLONE ID: 772051; Grant No. 320030_169670/1 Swiss National Science Foundation, Berne, Switzerland; Fondazione Fidinam, Lugano, Switzerland; Nelia & Amadeo Barletta Foundation, Lausanne, Switzerland; Fond'Action, Lausanne, Switzerland.

Contributions: DR and GG designed the study, interpreted data, and wrote the manuscript; FD, RM, CF, and ES performed molecular studies, contributed to data interpretation and manuscript preparation; AB, VS, LTdB contributed to data analysis; FA, CT and SD performed cell studies; LDP, CD, SR, RA, AP, SF, SS, CJ, AAK, DP, FRM, IDG, FF, AC, FZ, RB, FMR, CV, AC, GMR, RMa, MC, OP, AT, LL, MM, DD, PW, KM, PT, SL, FB, GDP, ACu, AF, RLB and MCa provided study material and contributed to manuscript revision; VG and RF contributed to data interpretation and manuscript revision. Conflict-of-interest disclosure: The authors declare no competing financial interests.